Skip to content
value.today

Stem Cell Assurance, Inc.

Total raised
$3 M
2 rounds on record
Latest round
$2 M
Apr 2012
First round on record
Nov 2010
Today
Went public
See the company page

Stem Cell Assurance, Inc. is listed today as BioRestorative Therapies, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Stem Cell Assurance, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2025$1 MPrivate placement after listingUnder $2 million

Stem Cell Assurance, Inc.: Private sale, Oct 2025

Investors in this round

16 investors had bought by the notice of Oct 9, 2025: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Francisco Silva · Director, Executive Officer
  • Lance Alstodt · Director, Executive Officer
  • Robert Kristal · Executive Officer
  • David A Rosa · Director
  • Nickolay V Kukekov · Director
  • Patrick F Williams · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cova Capital Partners LLC (CRD 109761) · Syosset, New YorkSold in all US states

Remarks in the notice

  • On fees: “The amounts shown above exclude the sales commissions payable in connection with the concurrent public offering relating to the offer and sale of shares of the Company's common stock.”
  • On the use of proceeds: “The amounts shown above exclude the salaries and fees payable to the executive officers and directors in the ordinary course of business.”

Signed by Robert Kristal, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 9, 2025. Read the notice at the SEC.

equity, optionsSEC
Jan 2014$14 MPrivate placement after listing$10 to $50 million

Stem Cell Assurance, Inc.: Private sale, Jan 2014

Investors in this round

81 investors had bought by the notice of May 9, 2016: 81 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
$2,725,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Edward L. Field · Executive Officer · President, Disc/Spine Division
  • Francisco Jeffrey Silva · Executive Officer · Vice President of Research and Development and Assistant Secretary
  • Mandy Jeffrey Clyde · Executive Officer · Vice President of Operations and Secretary
  • Mark Weinreb · Executive Officer, Director · Chief Executive Officer, Chairman of the Board and President
  • A. Jeffrey Radov · Director
  • Charles S. Ryan · Director
  • John M. Desmarais · Director
  • Paul Jude Tonna · Director
  • Robert B. Catell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark Weinreb, Chief Executive Officer. Source: SEC Form D and 2 amendments, newest notice filed May 9, 2016. Read the notice at the SEC.

equity, optionsSEC
Apr 2012$2 MNo. 2Under $2 million

Stem Cell Assurance, Inc.: Raise no. 2, Apr 2012

Investors in this round

6 investors had bought by the notice of Apr 18, 2012: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$150,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Nevada

People named in the notice

  • Mandy Clark · Executive Officer
  • Mark Weinreb · Executive Officer, Director · Chief Executive Officer and Chairman of the Board
  • A. Jeffrey Radov · Director
  • Joel San Antonio · Director
  • Gloria Jeffrey McConnell · Promoter
  • Tommy Jeffrey Berger · Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark Weinreb, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 18, 2012. Read the notice at the SEC.

equity, debt, optionsSEC
Nov 2010$1 MNo. 1Under $2 million

Stem Cell Assurance, Inc.: Raise no. 1, Nov 2010

Investors in this round

15 investors had bought by the notice of Mar 9, 2011: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $4 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$75,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Nevada

People named in the notice

  • Mandy Clark · Executive Officer, Director
  • Mark Weinreb · Executive Officer, Director
  • Richard Proodian · Executive Officer, Director
  • Joseph Ross · Director
  • Kurt Wagner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark Weinreb, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 9, 2011. Read the notice at the SEC.

equity, debtSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company BioRestorative Therapies, Inc., its revenue in fiscal 2025 came from these product and service lines: Royalty $60,000 (17%).

    Annual report (SEC XBRL) · Dec 2025

  • Stem Cell Assurance, Inc. had revenue of up to $1 million when it filed its newest notice of a funding round (Oct 2025).

    SEC Form D (revenue range) · Oct 2025

  • Revenue range over time, as stated in its notices: no revenue in 2012; revenue of up to $1 million in 2016; revenue of up to $1 million in 2025.

    SEC Form D (revenue range) · Oct 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2025

Products and services#

No products or services of Stem Cell Assurance, Inc. are on record.

Investors#

No investor of Stem Cell Assurance, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 15 investors.

Largest shareholders today

Institutions holding BioRestorative Therapies, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Stem Cell Assurance, Inc.
NameRoleNamed in
Francisco SilvaExecutive officerOct 2025
Lance AlstodtExecutive officerOct 2025
Robert KristalExecutive officerOct 2025
Edward L. FieldPresident, Disc/Spine DivisionMay 2016
Francisco Jeffrey SilvaVice President of Research and Development and Assistant SecretaryMay 2016
Mandy Jeffrey ClydeVice President of Operations and SecretaryMay 2016
Mark WeinrebChief Executive Officer, Chairman of the Board and PresidentMay 2016
Mandy ClarkExecutive officerApr 2012
Richard ProodianExecutive officerMar 2011
David A RosaDirectorOct 2025
Francisco SilvaDirectorOct 2025
Lance AlstodtDirectorOct 2025
Nickolay V KukekovDirectorOct 2025
Patrick F WilliamsDirectorOct 2025
A. Jeffrey RadovDirectorMay 2016
Charles S. RyanDirectorMay 2016
John M. DesmaraisDirectorMay 2016
Mark WeinrebChief Executive Officer, Chairman of the Board and PresidentMay 2016
Paul Jude TonnaDirectorMay 2016
Robert B. CatellDirectorMay 2016
Joseph B. SwiaderDirectorJan 2015
Joel San AntonioDirectorApr 2012
Joseph RossDirectorMar 2011
Kurt WagnerDirectorMar 2011
Mandy ClarkDirectorMar 2011
Richard ProodianDirectorMar 2011
Gloria Jeffrey McConnellPromoterApr 2012
Tommy Jeffrey BergerPromoterApr 2012

Went public since 2012. Its SEC number is that of a company listed on a stock exchange.